Moderna & Merck plan Phase 3 trial for cancer vaccine with Keytruda

Moderna & Merck plan Phase 3 trial for cancer vaccine with Keytruda

Source: 
Biopharma Reporter
snippet: 

An mRNA cancer vaccine, in combination with Keytruda, reduced the risk of recurrence or death in melanoma patients by 44% compared to Keytruda alone, according to Phase 2b data. Merck and Moderna plan to initiate a Phase 3 study in the coming months.